Black Diamond Therapeutics Inc Cash Flow-to-Debt Ratio
Black Diamond Therapeutics Inc cash flow-to-debt ratio. Black Diamond Therapeutics Inc (BDTX) has a Cash Flow-to-Debt Ratio of -0.25x as of June 2026, meaning its operating cash flow of $-7.14 Million could theoretically repay 0% of its total liabilities ($28.94 Million) in one year. Check Black Diamond Therapeutics Inc (BDTX) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Black Diamond Therapeutics Inc (2017–2025)
Cash flow-to-debt ratio of Black Diamond Therapeutics Inc from 2017 to 2025. Historical debt coverage capacity for Black Diamond Therapeutics Inc across 9 annual periods. Check Black Diamond Therapeutics Inc (BDTX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Black Diamond Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2017–2025)
Black Diamond Therapeutics Inc cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Black Diamond Therapeutics Inc. For the full cash flow conversion analysis, see Black Diamond Therapeutics Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.96x | $29.61 Million | $30.80 Million | ▲ +160.7% |
| 2024 | -1.58x | $-62.30 Million | $39.35 Million | ▲ +0.7% |
| 2023 | -1.59x | $-66.72 Million | $41.83 Million | ▲ +24.0% |
| 2022 | -2.10x | $-85.08 Million | $40.56 Million | ▼ -8.5% |
| 2021 | -1.93x | $-100.15 Million | $51.78 Million | ▲ +18.7% |
| 2020 | -2.38x | $-52.15 Million | $21.91 Million | ▼ -1881.6% |
| 2019 | -0.12x | $-24.67 Million | $205.45 Million | ▲ +4.3% |
| 2018 | -0.13x | $-8.45 Million | $67.37 Million | ▲ +21.6% |
| 2017 | -0.16x | $-2.35 Million | $14.70 Million | — |